Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative has signed a licensing and development accord to access narrow-spectrum Kinase inhibitors of Pulmatrix Inc (NASDAQ:PULM). As per the terms of the deal, Lung Cancer Initiative will initially pay an upfront amount of $7.2 million to Pulmatrix. The company will pay an additional amount of $2 million on […]
Pulmatrix Inc (NASDAQ:PULM)
Recent Posts
Colombia Oil and Gas 2023 Congress – Status and Developments Prospects of Oil and Gas industry in Latin America
Mike The Pike Productions, Inc. (OTC: MIKP) Announces Virtual Shareholder Conference July 25, 2023
Künstliche Intelligenz im Kinderherz-Zentrum
Auri Inc. – Dividend, Retirement Timelines and Expectations
Auto Parts 4Less Group, Inc. Unveils Significant Business Progress and Future Plans in Latest Investor Update
Sign Up To Get Our Instant Alerts!
Popular Post
- Mike The Pike Productions, Inc. (OTC: MIKP) Announces Virtual Shareholder Conference July 25, 2023 37 views
- Futuris Company Expands With Historic Building Purchase 34 views
- Auto Parts 4Less Group, Inc. Unveils Significant Business Progress and Future Plans in Latest Investor Update 34 views
- Tesla Suspends Hiring Further Set to Lay Off 10% of its Labor Force 34 views
- Colombia Oil and Gas 2023 Congress – Status and Developments Prospects of Oil and Gas industry in Latin America 33 views